Interestingly, patients harboring DLK1 mutations showed more metabolic abnormalities, including glucose intolerance, type 2 diabetes mellitus, and obesity, than CPP patients not harboring DLK1 mutations [46]. This evidence concerns the gene DLK1 and type 2 diabetes mellitus.